Program
ZSP1273
Also written as “ZSP1273 600 mg”, “ZSP1273 200 mg” and “ZSP1273 granules”.
Its studies are mostly in Influenza, Human · Renal Insufficiency, led by Guangdong Zhongsheng Pharmaceutical.
Furthest: phase 3, since Dec 13, 202014 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangdong Zhongsheng Pharmaceutical | 140 open or running | phase 3since Dec 13, 2020 | Sep 18, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 18, 2018First study: phase 1 study in Influenza, HumanFirst studyNCT03679143 · 103 enrolled · China
- Jul 10, 2019Phase 2 study in Influenza ANCT04024137 · 172 enrolled · China
- Dec 13, 2020Phase 3 study in Influenza ANCT04683406 · 750 enrolled · China
- Sep 29, 2021Phase 1 study in Drug-drug InteractionNCT05108051 · 36 enrolled · China
- May 4, 20232 phase 1 studiesNCT05873426, NCT05856513
- Jun 27, 2023Phase 1 study in Drug Drug InteractionNCT05942365 · 28 enrolled · China
- Jul 6, 2023Phase 1 study in Drug Drug InteractionNCT05954624 · 49 enrolled · China
- Nov 20, 20232 phase 1 studiesNCT06157450, NCT06164431
- Jan 31, 2024Phase 1 study in Renal InsufficiencyNCT06248567 · 16 enrolled · China
- Oct 14, 2024Phase 2 study in Influenza aNCT06656026 · 72 enrolled · China
- Nov 13, 20252 phase 3 studiesNCT07229820, NCT07229807
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07229820Influenza A · China | 3 | Completed | Dec 22, 2025 | 157 |
| NCT07229807Influenza a · China | 3 | Completed | Jan 17, 2026 | 120 |
| NCT06656026Influenza a · China | 2 | Completed | Jun 30, 2025 | 72 |
| NCT06248567Renal Insufficiency · China | 1 | Completed | Apr 30, 2024 | 16 |
| NCT06164431Bioequivalence · China | 1 | Completed | Dec 15, 2023 | 32 |
| NCT06157450Elder · China | 1 | Completed | Nov 1, 2023 | 32 |
| NCT05954624Drug Drug Interaction · China | 1 | Completed | Nov 20, 2023 | 49 |
| NCT05942365Drug Drug Interaction · China | 1 | Completed | Jul 21, 2023 | 28 |
| NCT05873426Pharmacokinetics · China | 1 | Completed | Apr 28, 2023 | 6 |
| NCT05856513Hepatic Impairment · China | 1 | Completed | Jul 4, 2023 | 24 |
| NCT05108051Drug-drug Interaction · China | 1 | Completed | Mar 17, 2021 | 36 |
| NCT04683406Influenza A · China | 3 | Completed | Apr 1, 2023 | 750 |
| NCT04024137Influenza A · China | 2 | Completed | May 18, 2020 | 172 |
| NCT03679143Influenza, Human · China | 1 | Completed | Mar 19, 2019 | 103 |
How it is read
Names in the registry
- “ZSP1273”, 11 entries
- “ZSP1273 600 mg”, 2 entries
- “ZSP1273 200 mg”, 2 entries
- “ZSP1273 granules”, 1 entry
- “[14C] ZSP1273”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.